we'll see in the coming months whether orders ramp up in correlation to the budgeted money for cameras announced and planned for 2015. could be Taser's biggest year, revenue-wise. more needs to flow to the bottom line, imo, so mgt needs to step up cost controls.
the "effect" on REITs should take awhile, imo, possibly not until next late next year, if at all.
the software is not rocket science (mostly database management) and the newer companies will have the edge, imo. ex-SalesForce guys just sold out to Sugar...more to come?
wow...market is sensitive
not really looking for agreement, just good discussion...there are definitely investor trading conflicts that could result from "hype" re: interim study results, if known outside FDA & company. imo.
i don't know if companies traditionally use partial clinical study results in patent apps...check with FDA.